Overview
The inventors engineered a novel stabilized plasmid selection system incorporating the gene mchI, conferring immunity against a natural antimicrobial peptide called microcin H47, which can be incorporated into the bacterial growth medium. There are no known clinical uses for microcin H47, so this approach is expected to meet vaccine regulatory requirements.
Applications
-Vaccine development as alternate system for plasmid selection in bacterial live vectors that will improve regulatory acceptability of vaccine. -Research tool for plasmid selection.
Advantages
Microcin-based selection system does not require engineering of the bacterial strain and does not rely on antibiotic resistance markers.
Stage of Development
This approach was successfully tested in two clinically proven vaccine strains.
R&D Required
Implementation as research tool or in vaccine development.
Licensing Potential
UMB seeks commercialization partners.
Contact Info
Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: [email protected]
Phone: (410) 706-2380